TRPM2 and pancreatic ductal adenocarcinoma: Consistent with our study, F. Morandi concluded that inactivation of the CD38-cADPR axis might serve as a novel therapeutic intervention in lung cancer and a recent report indicated that TRPM2 was linked with poor prognosis in patients with pancreatic ductal adenocarcinoma [34, 35].